MedicalCountermeaures.gov - Home

Public Health Emergency

U.S. Department of Health & Human Services

Presentations

Conference Home

October 29-30, 2018

8:00 AM to 5:00 PM Daily

Washington, D.C.

1000 H Street NW

Printable Version

Print this page

BID18_Agenda_and_Breakout_Session

We are currently completing 508 compliance on all presentations that will be posted; however, please email us attechwatchinbox@hhs.gov to receive compliant files.

Day 1: Monday, October 29

8:30-8:45	Welcome: Robert Kadlec, MD, MTM&H, MS Assistant Secretary for Preparedness and Response
8:45-9:10	Keynote Speaker: *Steven H. Walker, PhD* Director, DARPA
9:15-9:35	Leadership Perspective: ADM Brett Giroir (PDF - 1.3MB) Assistant Secretary for Health
9:40-9:55	Partner Perspective: Phil Gomez, PhD (PDF - 1.4MB) CEO, SIGA Technologies, Inc.
10:00-10:15	Partner Perspective: Gordon Naylor (PDF - 1.5MB) President, Seqirus

10:15-10:30	BREAK
10:30-12:00	BARDA Update Director's Report: (PDF - 9.6MB): Rick Bright, PhD Chemical, Biological, Radiological and Nuclear Threats Program: (PDF - 2.9MB): Chris Houchens, PhD Influenza and Emerging Infectious Diseases Program: (PDF - 1.6MB): Robert Johnson, PhD Division of Research, Innovation and Ventures (DRIVe): (PDF - 2MB): Tyler Merkeley, MS, MBA BARDA Contracts, Management and Acquisitions: (PDF - 1.7MB): S. Kyle Roberts, JD
12:00-1:00	LUNCH

TIME	Session	Session	Session
1:00 - 2:00	CBRN Programs Vaccines (PDF - 1.6MB) Antitoxins and Antivirals (PDF - 1.3MB) Antibacterials (PDF - 1.4MB)	DRIVE Innovation: Accelerators (PDF -1.0MB)	Lightning Talks (PDF - 2.4MB)
2:00 - 2:15	Break/Networking Lounge
2:15 - 3:15	CBRN Programs Radiological and Nuclear MCMs (PDF - 1.5MB) Chemical MCMs (PDF - 1.9MB) Thermal Burns (PDF - 2.5MB) Biodosimetry and other CBRN Diagnostics (PDF - 1.2MB)	Addressing AMR: CARB-X and other Models (PDF - 2.9MB)	Establishing a Whole of Government Approach to ADM (PDF - 1.2MB)
3:15 - 3:30	Break/Networking Lounge
3:30 - 4:30	Influenza and Emerging Infectious Disease Programs Vaccine Development (PDF - 1.2MB) Vaccine Stockpile (PDF - 1.7MB) Therapeutics (PDF - 1.4MB) Diagnostics & Respiratory Protection (PDF - 1MB)	New Approaches to Combating Opioids	Project BioShield & the Strategic National Stockpile

Day 2: Tuesday, October 30

8:45	*Welcome Back: Rick Bright, PhD* (PDF - 0.2MB)** BARDA Director
9:00-9:30	Keynote Speaker: Martine Rothblatt, PhD, JD (PDF - 5.5MB) CEO, United Therapeutics
9:35-10:05	Conversation with Robert Kadlec, MD, MTM&H, MS (PDF - 0.1MB) Assistant Secretary for Preparedness and Response Moderator: Steve Brozak, DMH, MBA, CEO, WBB Securities
10:05-10:25	BREAK - *Meet & Greet with BARDA Director*
10:25-11:25	Venture Capital Perspectives: Panel Discussion (PDF - 0.5MB) Patrick Heron, Managing General Partner, Frazier Healthcare Partners Andrew Levin, MD, PhD, Managing Director, RA Capital Management Ankit Mahadevia, MD, President & CEO, Spero Therapeutics Moderator: Jay Lichter, PhD, Avalon Ventures
11:30-12:00	Featured Speaker: Melinda Richter Global Head, Johnson & Johnson Innovation, JLABS

12:00-1:00	LUNCH

TIME	Session	Session	Session
1:00-2:00	DRIVe ENACT (PDF -1.0MB) Solving Sepsis (PDF -1.2MB) EZ BAA (PDF -1.0MB)	DoD/Collaborating on MCM Priorities	Partnering with BARDA: TechWatch to BAA
2:00-2:15	Break/Networking Lounge
2:15-3:15	Perspectives in Pandemic Influenza Preparedness Perspectives on Pandemic Influenza Preparedness (PDF - 0.7MB) Perspectives in Pandemic Influenza Preparedness (PDF - 0.2MB)	Developing Nonclinical Models with Partners Non Clinical Network: Developing Nonclinical Models with Partners (PDF - 1.2MB) Harmonization of BARDA’s Non-Clinical Models of Radiation Injury (PDF - 2.1MB) Scopolamine Efficacy (PDF - 1.2MB)	BARDA Public-Private Partnership Case Studies The Plazomicin Project (PDF - 0.3MB) Industry Benefits of a BARDA Partnership (PDF - 0.1MB) TPOXX® Project (PDF - 0.7MB) TPOXX® – A Smallpox Antiviral (PDF - 0.2MB) USG-Argentum Collaboration Supports Repurposing of Commercial Burn Dressing for Radiation Injury(Silverlon®) (PDF - 0.3MB) Silverlon by Argentum (PDF - 0.4MB)
3:15-3:30	Break/Networking Lounge
3:30-4:30	Emergency Use Authorizations for MCMs in an Emergency Emergency Use Authorization for MCMs (PDF - 3.5MB) FDA Emergency Use Authorization: Zika (PDF - 1.0MB) Current EUAs for BARDA Zika Program (PDF - 0.1MB)	FDA/Regulatory Considerations for MCM Development Regulatory Considerations for MCM Development (PDF - 0.7MB)	Repurposing for Chemical Medical Countermeasures

Presented By

Contact Us

Question or concerns:

email

Connect With Us